Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target

go back to reference Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ, Senni M, Triggiani M, Butler J, Gheorghiade M (2016) Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 18:54–65PubMedCrossRef Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ, Senni M, Triggiani M, Butler J, Gheorghiade M (2016) Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 18:54–65PubMedCrossRef

go back to reference Komajda M, Lam CS (2014) Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35:1022–1032PubMedCrossRef Komajda M, Lam CS (2014) Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35:1022–1032PubMedCrossRef

go back to reference Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269PubMedCrossRef Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269PubMedCrossRef

go back to reference Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259PubMedCrossRef Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259PubMedCrossRef

go back to reference Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the acute decompensated heart failure National Registry (ADHERE) database. J Am Coll Cardiol 47:76–84PubMedCrossRef Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the acute decompensated heart failure National Registry (ADHERE) database. J Am Coll Cardiol 47:76–84PubMedCrossRef

go back to reference Chan MM, Lam CS (2013) How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 15:604–613PubMedCrossRef Chan MM, Lam CS (2013) How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 15:604–613PubMedCrossRef

go back to reference Vaduganathan M, Patel RB, Michel A, Shah SJ, Senni M, Gheorghiade M, Butler J (2017) Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol 69:556–569PubMedCrossRef Vaduganathan M, Patel RB, Michel A, Shah SJ, Senni M, Gheorghiade M, Butler J (2017) Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol 69:556–569PubMedCrossRef

go back to reference Aro AL, Reinier K, Rusinaru C, Uy-Evanado A, Darouian N, Phan D, Mack WJ, Jui J, Soliman EZ, Tereshchenko LG, Chugh SS (2017) Electrical risk score beyond the left ventricular ejection fraction: prediction of sudden cardiac death in the Oregon sudden unexpected death study and the atherosclerosis risk in communities study. Eur Heart J 38:3017–3025PubMedPubMedCentralCrossRef Aro AL, Reinier K, Rusinaru C, Uy-Evanado A, Darouian N, Phan D, Mack WJ, Jui J, Soliman EZ, Tereshchenko LG, Chugh SS (2017) Electrical risk score beyond the left ventricular ejection fraction: prediction of sudden cardiac death in the Oregon sudden unexpected death study and the atherosclerosis risk in communities study. Eur Heart J 38:3017–3025PubMedPubMedCentralCrossRef

go back to reference Vaduganathan M, Patel RB, Shah SJ, Butler J (2016) Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? Heart Fail Rev 21:455–462PubMedCrossRef Vaduganathan M, Patel RB, Shah SJ, Butler J (2016) Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? Heart Fail Rev 21:455–462PubMedCrossRef

go back to reference Lane RE, Cowie MR, Chow AW (2005) Prediction and prevention of sudden cardiac death in heart failure. Heart 91:674–680PubMedPubMedCentralCrossRef Lane RE, Cowie MR, Chow AW (2005) Prediction and prevention of sudden cardiac death in heart failure. Heart 91:674–680PubMedPubMedCentralCrossRef

go back to reference Tomaselli GF, Zipes DP (2004) What causes sudden death in heart failure? Circ Res 95:754–763PubMedCrossRef Tomaselli GF, Zipes DP (2004) What causes sudden death in heart failure? Circ Res 95:754–763PubMedCrossRef

go back to reference Vaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Hegde SM, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD (2018) Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial. JACC Heart Fail 6:653–661PubMedCrossRef Vaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Hegde SM, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD (2018) Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial. JACC Heart Fail 6:653–661PubMedCrossRef

go back to reference Lund LH, Benson L, Dahlstrom U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308:2108–2117PubMedCrossRef Lund LH, Benson L, Dahlstrom U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308:2108–2117PubMedCrossRef

go back to reference Kutyifa V, Beck C, Brown MW, Cannom D, Daubert J, Estes M, Greenberg H, Goldenberg I, Hammes S, Huang D, Klein H, Knops R, Kosiborod M, Poole J, Schuger C, Singh JP, Solomon S, Wilber D, Zareba W, Moss AJ, MADIT S-ICD Executive Committee (2017) Multicenter automatic defibrillator implantation trial-subcutaneous implantable cardioverter defibrillator (MADIT S-ICD): design and clinical protocol. Am Heart J 189:158–166PubMedCrossRef Kutyifa V, Beck C, Brown MW, Cannom D, Daubert J, Estes M, Greenberg H, Goldenberg I, Hammes S, Huang D, Klein H, Knops R, Kosiborod M, Poole J, Schuger C, Singh JP, Solomon S, Wilber D, Zareba W, Moss AJ, MADIT S-ICD Executive Committee (2017) Multicenter automatic defibrillator implantation trial-subcutaneous implantable cardioverter defibrillator (MADIT S-ICD): design and clinical protocol. Am Heart J 189:158–166PubMedCrossRef

go back to reference Risgaard B, Lynge TH, Wissenberg M, Jabbari R, Glinge C, Gislason GH, Haunsø S, Winkel BG, Tfelt-Hansen J (2015) Risk factors and causes of sudden noncardiac death: a nationwide cohort study in Denmark. Heart Rhythm 12:968–974PubMedCrossRef Risgaard B, Lynge TH, Wissenberg M, Jabbari R, Glinge C, Gislason GH, Haunsø S, Winkel BG, Tfelt-Hansen J (2015) Risk factors and causes of sudden noncardiac death: a nationwide cohort study in Denmark. Heart Rhythm 12:968–974PubMedCrossRef

go back to reference Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay S, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392PubMedCrossRef Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay S, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392PubMedCrossRef

go back to reference Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV (2012) Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 18:749–754PubMedCrossRef Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV (2012) Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 18:749–754PubMedCrossRef

go back to reference Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA (2004) Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation 110:2180–2183PubMedCrossRef Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA (2004) Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation 110:2180–2183PubMedCrossRef

go back to reference Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray J, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE, I-Preserve Investigators (2010) Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-Preserve) trial. Circulation 121:1393–1405PubMedCrossRef Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray J, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE, I-Preserve Investigators (2010) Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-Preserve) trial. Circulation 121:1393–1405PubMedCrossRef

go back to reference Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, McKelvie RS, Massie B, Carson PE (2014) A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 16:1175–1182PubMedCrossRef Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, McKelvie RS, Massie B, Carson PE (2014) A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 16:1175–1182PubMedCrossRef

go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMedCrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMedCrossRef

go back to reference Narang R, Cleland JG, Erhardt L et al (1996) Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17:1390–1403PubMedCrossRef Narang R, Cleland JG, Erhardt L et al (1996) Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17:1390–1403PubMedCrossRef

go back to reference Nikolaidou T, Johnson MJ, Ghosh JM, Marincowitz C, Shah S, Lammiman MJ, Schilling RJ, Clark AL (2018) Postmortem ICD interrogation in mode of death classification. J Cardiovasc Electrophysiol 29:573–583PubMedCrossRef Nikolaidou T, Johnson MJ, Ghosh JM, Marincowitz C, Shah S, Lammiman MJ, Schilling RJ, Clark AL (2018) Postmortem ICD interrogation in mode of death classification. J Cardiovasc Electrophysiol 29:573–583PubMedCrossRef

go back to reference Orn S, Dickstein K (2002) How do heart failure patients die? Eur Heart J Suppl 4:D59–D65CrossRef Orn S, Dickstein K (2002) How do heart failure patients die? Eur Heart J Suppl 4:D59–D65CrossRef

go back to reference Tromp J, MacDonald MR, Tay WT et al (2018) Heart failure with preserved ejection fraction in the young. Circulation 138:2763–2773PubMedCrossRef Tromp J, MacDonald MR, Tay WT et al (2018) Heart failure with preserved ejection fraction in the young. Circulation 138:2763–2773PubMedCrossRef

go back to reference Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, Yokoshiki H, Tsutsui H, JCARE-CARD Investigators (2012) Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 76:1662–1669PubMedCrossRef Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, Yokoshiki H, Tsutsui H, JCARE-CARD Investigators (2012) Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 76:1662–1669PubMedCrossRef

go back to reference Aschauer S, Zotter-Tufaro C, Duca F, Kammerlander A, Dalos D, Mascherbauer J, Bonderman D (2017) Modes of death in patients with heart failure and preserved ejection fraction. Int J Cardiol 228:422–426PubMedCrossRef Aschauer S, Zotter-Tufaro C, Duca F, Kammerlander A, Dalos D, Mascherbauer J, Bonderman D (2017) Modes of death in patients with heart failure and preserved ejection fraction. Int J Cardiol 228:422–426PubMedCrossRef

go back to reference Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35:3452–3462PubMedPubMedCentralCrossRef Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35:3452–3462PubMedPubMedCentralCrossRef

go back to reference Mikami Y, Jolly U, Heydari B et al (2017) Right ventricular ejection fraction is incremental to left ventricular ejection fraction for the prediction of future arrhythmic events in patients with systolic dysfunction. Circ Arrhythm Electrophysiol 10(1):e004067 Mikami Y, Jolly U, Heydari B et al (2017) Right ventricular ejection fraction is incremental to left ventricular ejection fraction for the prediction of future arrhythmic events in patients with systolic dysfunction. Circ Arrhythm Electrophysiol 10(1):e004067

go back to reference Naksuk N, Tan N, Padmanabhan D et al (2018) Right ventricular dysfunction and long-term risk of sudden cardiac death in patients with and without severe left ventricular dysfunction. Circ Arrhythm Electrophysiol 11:e006091PubMedCrossRef Naksuk N, Tan N, Padmanabhan D et al (2018) Right ventricular dysfunction and long-term risk of sudden cardiac death in patients with and without severe left ventricular dysfunction. Circ Arrhythm Electrophysiol 11:e006091PubMedCrossRef

go back to reference Squire I (2004) Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy? Heart Fail Rev 9:337–345 discussion 47-51PubMedCrossRef Squire I (2004) Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy? Heart Fail Rev 9:337–345 discussion 47-51PubMedCrossRef

go back to reference Fallavollita JA, Dare JD, Carter RL, Baldwa S, Canty JM Jr (2017) Denervated myocardium is preferentially associated with sudden cardiac arrest in ischemic cardiomyopathy: a pilot competing risks analysis of cause-specific mortality. Circ Cardiovasc Imaging 10:e006446 Fallavollita JA, Dare JD, Carter RL, Baldwa S, Canty JM Jr (2017) Denervated myocardium is preferentially associated with sudden cardiac arrest in ischemic cardiomyopathy: a pilot competing risks analysis of cause-specific mortality. Circ Cardiovasc Imaging 10:e006446

go back to reference Greenberg B (2014) Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? J Am Coll Cardiol 63:2828–2830PubMedCrossRef Greenberg B (2014) Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? J Am Coll Cardiol 63:2828–2830PubMedCrossRef

go back to reference Hwang SJ, Melenovsky V, Borlaug BA (2014) Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 63:2817–2827PubMedCrossRef Hwang SJ, Melenovsky V, Borlaug BA (2014) Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 63:2817–2827PubMedCrossRef

go back to reference Tamarappoo BK, John BT, Reinier K et al (2012) Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation. J Am Heart Assoc 1:e001511PubMedPubMedCentralCrossRef Tamarappoo BK, John BT, Reinier K et al (2012) Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation. J Am Heart Assoc 1:e001511PubMedPubMedCentralCrossRef

go back to reference Stewart MH, Lavie CJ, Shah S, Englert J, Gilliland Y, Qamruddin S, Dinshaw H, Cash M, Ventura H, Milani R (2018) Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis 61:446–455PubMedCrossRef Stewart MH, Lavie CJ, Shah S, Englert J, Gilliland Y, Qamruddin S, Dinshaw H, Cash M, Ventura H, Milani R (2018) Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis 61:446–455PubMedCrossRef

go back to reference Gravez B, Tarjus A, Jaisser F (2013) Mineralocorticoid receptor and cardiac arrhythmia. Clin Exp Pharmacol Physiol 40:910–915PubMedCrossRef Gravez B, Tarjus A, Jaisser F (2013) Mineralocorticoid receptor and cardiac arrhythmia. Clin Exp Pharmacol Physiol 40:910–915PubMedCrossRef

go back to reference Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709–717PubMedCrossRef Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709–717PubMedCrossRef

go back to reference Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen D, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46:425–431PubMedCrossRef Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen D, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46:425–431PubMedCrossRef

go back to reference Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H, On behalf of the EPHESUS Investigators (2006) Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur J Heart Fail 8:295–301PubMedCrossRef Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H, On behalf of the EPHESUS Investigators (2006) Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur J Heart Fail 8:295–301PubMedCrossRef

go back to reference Shah SJ, Wasserstrom JA (2012) SERCA2a gene therapy for the prevention of sudden cardiac death: a future theranostic for heart failure? Circulation 126:2047–2050PubMedCrossRef Shah SJ, Wasserstrom JA (2012) SERCA2a gene therapy for the prevention of sudden cardiac death: a future theranostic for heart failure? Circulation 126:2047–2050PubMedCrossRef

go back to reference Packer M (1985) Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 72:681–685PubMedCrossRef Packer M (1985) Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 72:681–685PubMedCrossRef

go back to reference Al-Khatib SM, Shaw LK, O'Connor C, Kong M, Califf RM (2007) Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol 18:1231–1235PubMedCrossRef Al-Khatib SM, Shaw LK, O'Connor C, Kong M, Califf RM (2007) Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol 18:1231–1235PubMedCrossRef

go back to reference Donal E, Lund LH, Oger E, Hage C, Persson H, Reynaud A, Ennezat PV, Bauer F, Drouet E, Linde C, Daubert C, on behalf of the KaRen investigators (2015) New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) study. Eur J Heart Fail 17:680–688PubMedCrossRef Donal E, Lund LH, Oger E, Hage C, Persson H, Reynaud A, Ennezat PV, Bauer F, Drouet E, Linde C, Daubert C, on behalf of the KaRen investigators (2015) New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) study. Eur J Heart Fail 17:680–688PubMedCrossRef

go back to reference Tada T, Shiba N, Watanabe J, Matsuki M, Kagaya Y, Shinozaki T, Shirato K, Shimokawa H (2008) Prognostic value of anemia in predicting sudden death of patients with diastolic heart failure. Int J Cardiol 128:419–421PubMedCrossRef Tada T, Shiba N, Watanabe J, Matsuki M, Kagaya Y, Shinozaki T, Shirato K, Shimokawa H (2008) Prognostic value of anemia in predicting sudden death of patients with diastolic heart failure. Int J Cardiol 128:419–421PubMedCrossRef

go back to reference Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ (2003) Out-of-hospital cardiac arrest--the relevance of heart failure. The Maastricht circulatory arrest registry. Eur Heart J 24:1204–1209PubMedCrossRef Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ (2003) Out-of-hospital cardiac arrest--the relevance of heart failure. The Maastricht circulatory arrest registry. Eur Heart J 24:1204–1209PubMedCrossRef

go back to reference Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW (1991) Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol 18:377–382PubMedCrossRef Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW (1991) Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol 18:377–382PubMedCrossRef

go back to reference O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM (2000) Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 86:863–867PubMedCrossRef O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM (2000) Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 86:863–867PubMedCrossRef

go back to reference Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. Jama 300:431–433PubMedCrossRef Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. Jama 300:431–433PubMedCrossRef

go back to reference Whelton PK, Carey RM, Aronow WS, Casey de Jr, Collins KJ, Dennison Himmelfarb C, DePalma S, Gidding S, Jamerson KA, Jones DW, MacLaughlin E, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71:e13–e115PubMed Whelton PK, Carey RM, Aronow WS, Casey de Jr, Collins KJ, Dennison Himmelfarb C, DePalma S, Gidding S, Jamerson KA, Jones DW, MacLaughlin E, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71:e13–e115PubMed

go back to reference Tadic M, Cuspidi C, Frydas A, Grassi G (2018) The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more? Heart Fail Rev 23:631–639PubMedCrossRef Tadic M, Cuspidi C, Frydas A, Grassi G (2018) The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more? Heart Fail Rev 23:631–639PubMedCrossRef

go back to reference Rusinaru D, Houpe D, Szymanski C, Levy F, Marechaux S, Tribouilloy C (2014) Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 16:967–976PubMedCrossRef Rusinaru D, Houpe D, Szymanski C, Levy F, Marechaux S, Tribouilloy C (2014) Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 16:967–976PubMedCrossRef

go back to reference Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton APT, Anand IS, McKelvie RS, Komajda M, Zile MR, Carson PE, Gardner RS, Petrie MC, McMurray JJV (2015) Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circ Heart Fail 8:717–724PubMedCrossRef Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton APT, Anand IS, McKelvie RS, Komajda M, Zile MR, Carson PE, Gardner RS, Petrie MC, McMurray JJV (2015) Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circ Heart Fail 8:717–724PubMedCrossRef

go back to reference Shiga T, Hagiwara N, Ogawa H, Takagi A, Nagashima M, Yamauchi T, Tsurumi Y, Koyanagi R, Kasanuki H, Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) Investigators (2009) Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry. Heart 95:216–220PubMedCrossRef Shiga T, Hagiwara N, Ogawa H, Takagi A, Nagashima M, Yamauchi T, Tsurumi Y, Koyanagi R, Kasanuki H, Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) Investigators (2009) Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry. Heart 95:216–220PubMedCrossRef

go back to reference Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CM, TIMI Study Group (2009) Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. Am J Cardiol 104:475–479PubMedCrossRef Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CM, TIMI Study Group (2009) Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. Am J Cardiol 104:475–479PubMedCrossRef

go back to reference Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE, Sinnecker D, Raatikainen P, Exner DV (2018) Change in left ventricular ejection fraction following first myocardial infarction and outcome. JACC Clin Electrophysiol 4:672–682PubMedCrossRef Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE, Sinnecker D, Raatikainen P, Exner DV (2018) Change in left ventricular ejection fraction following first myocardial infarction and outcome. JACC Clin Electrophysiol 4:672–682PubMedCrossRef

go back to reference Kristensen SL, Jhund PS, Lee MMY et al (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther 31:545–549PubMedPubMedCentralCrossRef Kristensen SL, Jhund PS, Lee MMY et al (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther 31:545–549PubMedPubMedCentralCrossRef

go back to reference Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA (2018) Heart failure with preserved ejection fraction in diabetes: mechanisms and management. Can J Cardiol 34:632–643PubMedCrossRef Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA (2018) Heart failure with preserved ejection fraction in diabetes: mechanisms and management. Can J Cardiol 34:632–643PubMedCrossRef

go back to reference Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie R, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray J (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-PRESERVE trial (Irbesartan in heart failure with preserved ejection fraction). Circulation 135:724–735PubMedCrossRef Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie R, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray J (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-PRESERVE trial (Irbesartan in heart failure with preserved ejection fraction). Circulation 135:724–735PubMedCrossRef

go back to reference Junttila MJ, Kiviniemi AM, Lepojarvi ES et al (2018) Type 2 diabetes and coronary artery disease: preserved ejection fraction and sudden cardiac death. Heart Rhythm 15:1450–1456PubMedCrossRef Junttila MJ, Kiviniemi AM, Lepojarvi ES et al (2018) Type 2 diabetes and coronary artery disease: preserved ejection fraction and sudden cardiac death. Heart Rhythm 15:1450–1456PubMedCrossRef

go back to reference Sartipy U, Dahlstrom U, Fu M, Lund LH (2017) Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 5:565–574PubMedCrossRef Sartipy U, Dahlstrom U, Fu M, Lund LH (2017) Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 5:565–574PubMedCrossRef

go back to reference Ergatoudes C, Schaufelberger M, Andersson B, Pivodic A, Dahlstrom U, Fu M (2019) Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01430-0 [Epub ahead of print]PubMedPubMedCentralCrossRef Ergatoudes C, Schaufelberger M, Andersson B, Pivodic A, Dahlstrom U, Fu M (2019) Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clin Res Cardiol. https://​doi.​org/​10.​1007/​s00392-019-01430-0 [Epub ahead of print]PubMedPubMedCentralCrossRef

go back to reference Okuno K, Naito Y, Asakura M, Sugahara M, Ando T, Yasumura S, Nagai T, Saito Y, Yoshikawa T, Masuyama T, Anzai T (2019) Effective blood hemoglobin level to predict prognosis in heart failure with preserved left ventricular ejection fraction: results of the Japanese heart failure syndrome with preserved ejection fraction registry. Heart Vessel. https://doi.org/10.1007/s00380-019-01349-6 [Epub ahead of print]PubMedCrossRef Okuno K, Naito Y, Asakura M, Sugahara M, Ando T, Yasumura S, Nagai T, Saito Y, Yoshikawa T, Masuyama T, Anzai T (2019) Effective blood hemoglobin level to predict prognosis in heart failure with preserved left ventricular ejection fraction: results of the Japanese heart failure syndrome with preserved ejection fraction registry. Heart Vessel. https://​doi.​org/​10.​1007/​s00380-019-01349-6 [Epub ahead of print]PubMedCrossRef

go back to reference Kim IJ, Yang PS, Kim TH, Uhm JS, Pak HN, Lee MH, Sung JH, Joung B (2018) Relationship between anemia and the risk of sudden cardiac arrest- a nationwide cohort study in South Korea. Circ J 82:2962–2969PubMedCrossRef Kim IJ, Yang PS, Kim TH, Uhm JS, Pak HN, Lee MH, Sung JH, Joung B (2018) Relationship between anemia and the risk of sudden cardiac arrest- a nationwide cohort study in South Korea. Circ J 82:2962–2969PubMedCrossRef

go back to reference Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O’Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS (2019) Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail 7:25–32PubMedCrossRef Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O’Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS (2019) Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail 7:25–32PubMedCrossRef

go back to reference Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469PubMedCrossRef Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469PubMedCrossRef

go back to reference Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM (2014) Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2:260–268PubMedPubMedCentralCrossRef Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM (2014) Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2:260–268PubMedPubMedCentralCrossRef

go back to reference de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B (2013) Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 15:1095–1101PubMedCrossRef de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B (2013) Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 15:1095–1101PubMedCrossRef

go back to reference Gehlken C, Suthahar N, Meijers WC, de Boer RA (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14:75–92PubMedCrossRef Gehlken C, Suthahar N, Meijers WC, de Boer RA (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14:75–92PubMedCrossRef

go back to reference Cui Y, Qi X, Huang A, Li J, Hou W, Liu K (2018) Differential and predictive value of Galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction. Med Sci Monit 24:5139–5146PubMedPubMedCentralCrossRef Cui Y, Qi X, Huang A, Li J, Hou W, Liu K (2018) Differential and predictive value of Galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction. Med Sci Monit 24:5139–5146PubMedPubMedCentralCrossRef

go back to reference Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM (2015) Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17:214–223PubMedCrossRef Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM (2015) Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17:214–223PubMedCrossRef

go back to reference Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N (2019) Soluble ST2 and Galectin-3 and progression of CKD. Kidney Int Rep 4:103–111PubMedCrossRef Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N (2019) Soluble ST2 and Galectin-3 and progression of CKD. Kidney Int Rep 4:103–111PubMedCrossRef

go back to reference Pun PH (2014) The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis 21:480–488PubMedPubMedCentralCrossRef Pun PH (2014) The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis 21:480–488PubMedPubMedCentralCrossRef

go back to reference Franczyk-Skora B, Gluba-Brzozka A, Wranicz JK, Banach M, Olszewski R, Rysz J (2015) Sudden cardiac death in CKD patients. Int Urol Nephrol 47:971–982PubMedCrossRef Franczyk-Skora B, Gluba-Brzozka A, Wranicz JK, Banach M, Olszewski R, Rysz J (2015) Sudden cardiac death in CKD patients. Int Urol Nephrol 47:971–982PubMedCrossRef

go back to reference Santema BT, Kloosterman M, Van Gelder IC et al (2018) Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J 39:3867–3875PubMedCrossRef Santema BT, Kloosterman M, Van Gelder IC et al (2018) Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J 39:3867–3875PubMedCrossRef

go back to reference Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569–577PubMedCrossRef Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569–577PubMedCrossRef

go back to reference Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O’Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD (2017) Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail 5:241–252PubMedCrossRef Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O’Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD (2017) Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail 5:241–252PubMedCrossRef

go back to reference Chow SL, Maisel AS, Anand I et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135:e1054–e1e91PubMedCrossRef Chow SL, Maisel AS, Anand I et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135:e1054–e1e91PubMedCrossRef

go back to reference Rech M, Barandiaran Aizpurua A, van Empel V, van Bilsen M, Schroen B (2018) Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. Cardiovasc Res 114:782–793PubMedCrossRef Rech M, Barandiaran Aizpurua A, van Empel V, van Bilsen M, Schroen B (2018) Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. Cardiovasc Res 114:782–793PubMedCrossRef

go back to reference Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Siscovick D, Stevenson WG, Zipes DP, American Heart Association, American College of Cardiology Foundation, Heart Rhythm Society (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on clinical cardiology committee on electrocardiography and arrhythmias and council on epidemiology and prevention. Circulation 118:1497–1518PubMedCrossRef Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Siscovick D, Stevenson WG, Zipes DP, American Heart Association, American College of Cardiology Foundation, Heart Rhythm Society (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on clinical cardiology committee on electrocardiography and arrhythmias and council on epidemiology and prevention. Circulation 118:1497–1518PubMedCrossRef

go back to reference Goldberger JJ, Subacius H, Patel T, Cunnane R, Kadish AH (2014) Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63:1879–1889PubMedCrossRef Goldberger JJ, Subacius H, Patel T, Cunnane R, Kadish AH (2014) Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63:1879–1889PubMedCrossRef

go back to reference Zaman S, Goldberger JJ, Kovoor P (2019) Sudden death risk-stratification in 2018-2019: the old and the new. Heart Lung Circ 28:57–64PubMedCrossRef Zaman S, Goldberger JJ, Kovoor P (2019) Sudden death risk-stratification in 2018-2019: the old and the new. Heart Lung Circ 28:57–64PubMedCrossRef

go back to reference Cannon JA, Shen L, Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Carson PE, McMurray JJV (2016) Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail 18:1021–1031PubMedCrossRef Cannon JA, Shen L, Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Carson PE, McMurray JJV (2016) Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail 18:1021–1031PubMedCrossRef

go back to reference Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, Alehagen U (2013) Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 34:529–539CrossRefPubMed Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, Alehagen U (2013) Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 34:529–539CrossRefPubMed

go back to reference Wilcox JE, Rosenberg J, Vallakati A, Gheorghiade M, Shah SJ (2011) Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol 108:1760–1766PubMedPubMedCentralCrossRef Wilcox JE, Rosenberg J, Vallakati A, Gheorghiade M, Shah SJ (2011) Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol 108:1760–1766PubMedPubMedCentralCrossRef

go back to reference Masarone D, Limongelli G, Ammendola E, Verrengia M, Gravino R, Pacileo G (2018) Risk stratification of sudden cardiac death in patients with heart failure: an update. J Clin Med 7(11):436PubMedCentralCrossRef Masarone D, Limongelli G, Ammendola E, Verrengia M, Gravino R, Pacileo G (2018) Risk stratification of sudden cardiac death in patients with heart failure: an update. J Clin Med 7(11):436PubMedCentralCrossRef

go back to reference Hummel SL, Skorcz S, Koelling TM (2009) Prolonged electrocardiogram QRS duration independently predicts long-term mortality in patients hospitalized for heart failure with preserved systolic function. J Card Fail 15:553–560PubMedPubMedCentralCrossRef Hummel SL, Skorcz S, Koelling TM (2009) Prolonged electrocardiogram QRS duration independently predicts long-term mortality in patients hospitalized for heart failure with preserved systolic function. J Card Fail 15:553–560PubMedPubMedCentralCrossRef

go back to reference Joseph J, Claggett BC, Anand IS, Fleg JL, Huynh T, Desai AS, Solomon SD, O’Meara E, Mckinlay S, Pitt B, Pfeffer MA, Lewis EF (2016) QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 4:477–486PubMedCrossRef Joseph J, Claggett BC, Anand IS, Fleg JL, Huynh T, Desai AS, Solomon SD, O’Meara E, Mckinlay S, Pitt B, Pfeffer MA, Lewis EF (2016) QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 4:477–486PubMedCrossRef

go back to reference Gentile P, Paldino A, Cannata A et al (2019) Left bundle branch block in dilated cardiomyopathy with intermediate left ventricular dysfunction: clinical phenotyping and outcome correlates. Int J Cardiol 278:180–185PubMedCrossRef Gentile P, Paldino A, Cannata A et al (2019) Left bundle branch block in dilated cardiomyopathy with intermediate left ventricular dysfunction: clinical phenotyping and outcome correlates. Int J Cardiol 278:180–185PubMedCrossRef

go back to reference Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131:269–279PubMedCrossRef Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131:269–279PubMedCrossRef

go back to reference Chatterjee NA, Moorthy MV, Pester J, Schaecter A, Panicker GK, Narula D, Lee DC, Goldberger JJ, Kadish A, Cook NR, Albert CM, for the PRE-DETERMINE Study Group (2018) Sudden death in patients with coronary heart disease without severe systolic dysfunction. JAMA Cardiol 3:591–600PubMedPubMedCentralCrossRef Chatterjee NA, Moorthy MV, Pester J, Schaecter A, Panicker GK, Narula D, Lee DC, Goldberger JJ, Kadish A, Cook NR, Albert CM, for the PRE-DETERMINE Study Group (2018) Sudden death in patients with coronary heart disease without severe systolic dysfunction. JAMA Cardiol 3:591–600PubMedPubMedCentralCrossRef

go back to reference Chen X, Shenasa M, Borggrefe M et al (1994) Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients. Eur Heart J 15:76–82PubMedCrossRef Chen X, Shenasa M, Borggrefe M et al (1994) Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients. Eur Heart J 15:76–82PubMedCrossRef

go back to reference Becker R, Haass M, Ick D, Krueger C, Bauer A, Senges-Becker JC, Voss F, Hilbel T, Niroomand F, Katus HA, Schoels W (2003) Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy. Basic Res Cardiol 98:259–266PubMedCrossRef Becker R, Haass M, Ick D, Krueger C, Bauer A, Senges-Becker JC, Voss F, Hilbel T, Niroomand F, Katus HA, Schoels W (2003) Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy. Basic Res Cardiol 98:259–266PubMedCrossRef

go back to reference Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36:2793–2867PubMedCrossRef Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36:2793–2867PubMedCrossRef

go back to reference Manolis AS (2017) Sudden death risk stratification in non-ischemic dilated cardiomyopathy using old and new tools: a clinical challenge. Expert Rev Cardiovasc Ther 15:315–325PubMedCrossRef Manolis AS (2017) Sudden death risk stratification in non-ischemic dilated cardiomyopathy using old and new tools: a clinical challenge. Expert Rev Cardiovasc Ther 15:315–325PubMedCrossRef

go back to reference Al-Khatib SM, Stevenson WG, Ackerman MJ et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 72:e91–e220PubMedCrossRef Al-Khatib SM, Stevenson WG, Ackerman MJ et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 72:e91–e220PubMedCrossRef

go back to reference Poyhonen P, Kivisto S, Holmstrom M, Hanninen H (2014) Quantifying late gadolinium enhancement on CMR provides additional prognostic information in early risk-stratification of nonischemic cardiomyopathy: a cohort study. BMC Cardiovasc Disord 14:110PubMedPubMedCentralCrossRef Poyhonen P, Kivisto S, Holmstrom M, Hanninen H (2014) Quantifying late gadolinium enhancement on CMR provides additional prognostic information in early risk-stratification of nonischemic cardiomyopathy: a cohort study. BMC Cardiovasc Disord 14:110PubMedPubMedCentralCrossRef

go back to reference Di Marco A, Anguera I, Schmitt M et al (2017) Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy. Am Coll Cardiol HF 5:28–38 Di Marco A, Anguera I, Schmitt M et al (2017) Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy. Am Coll Cardiol HF 5:28–38

go back to reference Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK (2017) Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135:2106–2115PubMedPubMedCentralCrossRef Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK (2017) Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135:2106–2115PubMedPubMedCentralCrossRef

go back to reference Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 50:768–777PubMedCrossRef Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 50:768–777PubMedCrossRef

go back to reference Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group, de Backer G, Heagerty AM, Agewall S, Bochud M, Borghi C, Boutouyrie P, Brguljan J, Bueno H, Caiani EG, Carlberg B, Chapman N, Cífková R, Cleland JGF, Collet JP, Coman IM, de Leeuw PW, Delgado V, Dendale P, Diener HC, Dorobantu M, Fagard R, Farsang C, Ferrini M, Graham IM, Grassi G, Haller H, Hobbs FDR, Jelakovic B, Jennings C, Katus HA, Kroon AA, Leclercq C, Lovic D, Lurbe E, Manolis AJ, McDonagh TA, Messerli F, Muiesan ML, Nixdorff U, Olsen MH, Parati G, Perk J, Piepoli MF, Polonia J, Ponikowski P, Richter DJ, Rimoldi SF, Roffi M, Sattar N, Seferovic PM, Simpson IA, Sousa-Uva M, Stanton AV, van de Borne P, Vardas P, Volpe M, Wassmann S, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Tsioufis C, Lurbe E, Kreutz R, Bochud M, Rosei EA, Jelakovic B, Azizi M, Januszewics A, Kahan T, Polonia J, van de Borne P, Williams B, Borghi C, Mancia G, Parati G, Clement DL, Coca A, Manolis A, Lovic D, Benkhedda S, Zelveian P, Siostrzonek P, Najafov R, Pavlova O, de Pauw M, Dizdarevic-Hudic L, Raev D, Karpettas N, Linhart A, Olsen MH, Shaker AF, Viigimaa M, Metsärinne K, Vavlukis M, Halimi JM, Pagava Z, Schunkert H, Thomopoulos C, Páll D, Andersen K, Shechter M, Mercuro G, Bajraktari G, Romanova T, Trušinskis K, Saade GA, Sakalyte G, Noppe S, DeMarco DC, Caraus A, Wittekoek J, Aksnes TA, Jankowski P, Polonia J, Vinereanu D, Baranova EI, Foscoli M, Dikic AD, Filipova S, Fras Z, Bertomeu-Martínez V, Carlberg B, Burkard T, Sdiri W, Aydogdu S, Sirenko Y, Brady A, Weber T, Lazareva I, Backer TD, Sokolovic S, Jelakovic B, Widimsky J, Viigimaa M, Pörsti I, Denolle T, Krämer BK, Stergiou GS, Parati G, Trušinskis K, Miglinas M, Gerdts E, Tykarski A, de Carvalho Rodrigues M, Dorobantu M, Chazova I, Lovic D, Filipova S, Brguljan J, Segura J, Gottsäter A, Pechère-Bertschi A, Erdine S, Sirenko Y, Brady A (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104PubMedCrossRef Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group, de Backer G, Heagerty AM, Agewall S, Bochud M, Borghi C, Boutouyrie P, Brguljan J, Bueno H, Caiani EG, Carlberg B, Chapman N, Cífková R, Cleland JGF, Collet JP, Coman IM, de Leeuw PW, Delgado V, Dendale P, Diener HC, Dorobantu M, Fagard R, Farsang C, Ferrini M, Graham IM, Grassi G, Haller H, Hobbs FDR, Jelakovic B, Jennings C, Katus HA, Kroon AA, Leclercq C, Lovic D, Lurbe E, Manolis AJ, McDonagh TA, Messerli F, Muiesan ML, Nixdorff U, Olsen MH, Parati G, Perk J, Piepoli MF, Polonia J, Ponikowski P, Richter DJ, Rimoldi SF, Roffi M, Sattar N, Seferovic PM, Simpson IA, Sousa-Uva M, Stanton AV, van de Borne P, Vardas P, Volpe M, Wassmann S, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Tsioufis C, Lurbe E, Kreutz R, Bochud M, Rosei EA, Jelakovic B, Azizi M, Januszewics A, Kahan T, Polonia J, van de Borne P, Williams B, Borghi C, Mancia G, Parati G, Clement DL, Coca A, Manolis A, Lovic D, Benkhedda S, Zelveian P, Siostrzonek P, Najafov R, Pavlova O, de Pauw M, Dizdarevic-Hudic L, Raev D, Karpettas N, Linhart A, Olsen MH, Shaker AF, Viigimaa M, Metsärinne K, Vavlukis M, Halimi JM, Pagava Z, Schunkert H, Thomopoulos C, Páll D, Andersen K, Shechter M, Mercuro G, Bajraktari G, Romanova T, Trušinskis K, Saade GA, Sakalyte G, Noppe S, DeMarco DC, Caraus A, Wittekoek J, Aksnes TA, Jankowski P, Polonia J, Vinereanu D, Baranova EI, Foscoli M, Dikic AD, Filipova S, Fras Z, Bertomeu-Martínez V, Carlberg B, Burkard T, Sdiri W, Aydogdu S, Sirenko Y, Brady A, Weber T, Lazareva I, Backer TD, Sokolovic S, Jelakovic B, Widimsky J, Viigimaa M, Pörsti I, Denolle T, Krämer BK, Stergiou GS, Parati G, Trušinskis K, Miglinas M, Gerdts E, Tykarski A, de Carvalho Rodrigues M, Dorobantu M, Chazova I, Lovic D, Filipova S, Brguljan J, Segura J, Gottsäter A, Pechère-Bertschi A, Erdine S, Sirenko Y, Brady A (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104PubMedCrossRef

go back to reference Manolis AA, Manolis TA, Melita H, Manolis AS (2019) Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men's issue? Curr Hypertens Rep 21:22PubMedCrossRef Manolis AA, Manolis TA, Melita H, Manolis AS (2019) Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men's issue? Curr Hypertens Rep 21:22PubMedCrossRef

go back to reference Al-Gobari M, El Khatib C, Pillon F (2013) Gueyffier F beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 13:52PubMedPubMedCentralCrossRef Al-Gobari M, El Khatib C, Pillon F (2013) Gueyffier F beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 13:52PubMedPubMedCentralCrossRef

go back to reference Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMedCrossRef Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMedCrossRef

go back to reference Desai AS, McMurray JJ, Packer M et al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36:1990–1997PubMedCrossRef Desai AS, McMurray JJ, Packer M et al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36:1990–1997PubMedCrossRef

go back to reference Manolis AS, Manolis TA, Manolis AA, Melita H (2019) Neprilysin inhibitors: filling a gap in heart failure management, albeit amidst controversy and at a significant cost. Am J Cardiovasc Drugs 19:21–36PubMedCrossRef Manolis AS, Manolis TA, Manolis AA, Melita H (2019) Neprilysin inhibitors: filling a gap in heart failure management, albeit amidst controversy and at a significant cost. Am J Cardiovasc Drugs 19:21–36PubMedCrossRef

go back to reference Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride P, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70:776–803PubMedCrossRef Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride P, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70:776–803PubMedCrossRef

go back to reference Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779PubMedCrossRef Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779PubMedCrossRef

go back to reference Patel RB, Vaduganathan M (2018) Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream? Expert Rev Cardiovasc Ther 16:875–877PubMedPubMedCentralCrossRef Patel RB, Vaduganathan M (2018) Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream? Expert Rev Cardiovasc Ther 16:875–877PubMedPubMedCentralCrossRef

go back to reference Solomon SD, Rizkala AR, Lefkowitz MP et al (2018) Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ Heart Fail 11:e004962PubMedCrossRef Solomon SD, Rizkala AR, Lefkowitz MP et al (2018) Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ Heart Fail 11:e004962PubMedCrossRef

go back to reference Buonafine M, Bonnard B, Jaisser F (2018) Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens 31:1165–1174PubMedCrossRef Buonafine M, Bonnard B, Jaisser F (2018) Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens 31:1165–1174PubMedCrossRef

go back to reference He BJ, Anderson ME (2013) Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab 24:21–30PubMedCrossRef He BJ, Anderson ME (2013) Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab 24:21–30PubMedCrossRef

go back to reference Young MJ, Rickard AJ (2015) Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol 224:R1–R13PubMedCrossRef Young MJ, Rickard AJ (2015) Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol 224:R1–R13PubMedCrossRef

go back to reference Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54:1674–1682PubMedCrossRef Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54:1674–1682PubMedCrossRef

go back to reference Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail 17:634–642PubMedCrossRef Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail 17:634–642PubMedCrossRef

go back to reference Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A (2013) Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail 1:40–47PubMedPubMedCentralCrossRef Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A (2013) Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail 1:40–47PubMedPubMedCentralCrossRef

go back to reference Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH (2011) A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 4:1239–1249PubMedCrossRef Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH (2011) A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 4:1239–1249PubMedCrossRef

go back to reference Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF Investigators (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791PubMedCrossRef Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF Investigators (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791PubMedCrossRef

go back to reference Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455–462PubMedCrossRef Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455–462PubMedCrossRef

go back to reference Ravassa S, Trippel T, Bach D, Bachran D, González A, López B, Wachter R, Hasenfuss G, Delles C, Dominiczak AF, Pieske B, Díez J, Edelmann F (2018) Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20:1290–1299PubMedCrossRef Ravassa S, Trippel T, Bach D, Bachran D, González A, López B, Wachter R, Hasenfuss G, Delles C, Dominiczak AF, Pieske B, Díez J, Edelmann F (2018) Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20:1290–1299PubMedCrossRef

go back to reference Pandey A, Garg S, Matulevicius SA et al (2015) Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review. J Am Heart Assoc 4:e002137PubMedPubMedCentralCrossRef Pandey A, Garg S, Matulevicius SA et al (2015) Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review. J Am Heart Assoc 4:e002137PubMedPubMedCentralCrossRef

go back to reference Kapelios CJ, Murrow JR, Nuhrenberg TG, Montoro Lopez MN (2019) Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 24:367–377PubMedPubMedCentralCrossRef Kapelios CJ, Murrow JR, Nuhrenberg TG, Montoro Lopez MN (2019) Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 24:367–377PubMedPubMedCentralCrossRef

go back to reference Fukuta H, Sane DC, Brucks S, Little WC (2005) Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112:357–363PubMedCrossRef Fukuta H, Sane DC, Brucks S, Little WC (2005) Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112:357–363PubMedCrossRef

go back to reference Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H, on behalf of the CHART-2 Investigators’ (2015) Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 79:574–582PubMedCrossRef Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H, on behalf of the CHART-2 Investigators’ (2015) Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 79:574–582PubMedCrossRef

go back to reference Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B (2017) No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. PLoS One 12:e0171168PubMedPubMedCentralCrossRef Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B (2017) No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. PLoS One 12:e0171168PubMedPubMedCentralCrossRef

go back to reference Fishman GI, Chugh SS, Dimarco JP et al (2010) Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society workshop. Circulation 122:2335–2348PubMedPubMedCentralCrossRef Fishman GI, Chugh SS, Dimarco JP et al (2010) Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society workshop. Circulation 122:2335–2348PubMedPubMedCentralCrossRef

go back to reference Myerburg RJ (2018) Cardiac and noncardiac causes of apparent sudden arrhythmic deaths: shadows in a spectrum. Circulation 137:2701–2704PubMedCrossRef Myerburg RJ (2018) Cardiac and noncardiac causes of apparent sudden arrhythmic deaths: shadows in a spectrum. Circulation 137:2701–2704PubMedCrossRef

go back to reference Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, Yeh C, Colburn B, Clark NM, Khan R, Hart AP, Moffatt E (2018) Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD study. Circulation 137:2689–2700PubMedPubMedCentralCrossRef Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, Yeh C, Colburn B, Clark NM, Khan R, Hart AP, Moffatt E (2018) Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD study. Circulation 137:2689–2700PubMedPubMedCentralCrossRef

go back to reference Wellens HJ, Schwartz PJ, Lindemans FW et al (2014) Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J 35:1642–1651PubMedPubMedCentralCrossRef Wellens HJ, Schwartz PJ, Lindemans FW et al (2014) Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J 35:1642–1651PubMedPubMedCentralCrossRef

go back to reference Buxton AE, Waks JW, Shen C, Chen PS (2016) Risk stratification for sudden cardiac death in North America - current perspectives. J Electrocardiol 49:817–823PubMedCrossRef Buxton AE, Waks JW, Shen C, Chen PS (2016) Risk stratification for sudden cardiac death in North America - current perspectives. J Electrocardiol 49:817–823PubMedCrossRef

go back to reference Buxton AE (2017) Sudden death in ischemic heart disease - 2017. Int J Cardiol 237:64–66PubMedCrossRef Buxton AE (2017) Sudden death in ischemic heart disease - 2017. Int J Cardiol 237:64–66PubMedCrossRef

go back to reference Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE (2017) Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the sudden cardiac death in heart failure trial. JAMA Cardiol 2:767–774PubMedPubMedCentralCrossRef Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE (2017) Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the sudden cardiac death in heart failure trial. JAMA Cardiol 2:767–774PubMedPubMedCentralCrossRef

go back to reference Zhou W, Chen J (2013) I -123 metaiodobenzylguanidine imaging for predicting ventricular arrhythmia in heart failure patients. J Biomed Res 27:460–466PubMedPubMedCentral Zhou W, Chen J (2013) I -123 metaiodobenzylguanidine imaging for predicting ventricular arrhythmia in heart failure patients. J Biomed Res 27:460–466PubMedPubMedCentral

go back to reference Nakajima K, Scholte A, Nakata T et al (2017) Cardiac sympathetic nervous system imaging with (123)I-meta-iodobenzylguanidine: perspectives from Japan and Europe. J Nucl Cardiol 24:952–960PubMedCrossRef Nakajima K, Scholte A, Nakata T et al (2017) Cardiac sympathetic nervous system imaging with (123)I-meta-iodobenzylguanidine: perspectives from Japan and Europe. J Nucl Cardiol 24:952–960PubMedCrossRef

go back to reference Kato S, Saito N, Kirigaya H, Gyotoku D, Iinuma N, Kusakawa Y, Iguchi K, Nakachi T, Fukui K, Futaki M, Iwasawa T, Taguri M, Kimura K, Umemura S (2015) Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 191:314–319PubMedCrossRef Kato S, Saito N, Kirigaya H, Gyotoku D, Iinuma N, Kusakawa Y, Iguchi K, Nakachi T, Fukui K, Futaki M, Iwasawa T, Taguri M, Kimura K, Umemura S (2015) Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 191:314–319PubMedCrossRef